Palvella Therapeutics Net Profit Margin 2014-2024 | PVLA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Palvella Therapeutics net profit margin from 2014 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Palvella Therapeutics net profit margin from 2014 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$139.4B
Gilead Sciences (GILD)	$114.7B
Bristol Myers Squibb (BMY)	$113.7B
Vertex Pharmaceuticals (VRTX)	$102.8B
CSL (CSLLY)	$85.4B
Regeneron Pharmaceuticals (REGN)	$77.2B
GSK (GSK)	$69.7B
Argenex SE (ARGX)	$37.4B
Alnylam Pharmaceuticals (ALNY)	$30.4B
BioNTech SE (BNTX)	$27B
Biogen (BIIB)	$21.9B
Illumina (ILMN)	$21.2B
BeiGene (BGNE)	$17.9B
Moderna (MRNA)	$15.2B
Genmab (GMAB)	$13.7B
Incyte (INCY)	$13.2B
BioMarin Pharmaceutical (BMRN)	$12.5B
Insmed (INSM)	$12.3B
Sarepta Therapeutics (SRPT)	$11.6B
Bio-Techne Corp (TECH)	$11.5B
Exact Sciences (EXAS)	$10.4B
Vaxcyte (PCVX)	$10.2B
QIAGEN (QGEN)	$10.2B
Swedish Orphan Biovitrum (BIOVF)	$9.8B
Exelixis (EXEL)	$9.6B
Bio-Rad Laboratories (BIO.B)	$9.1B
Intra-Cellular Therapies (ITCI)	$8.9B
Roivant Sciences (ROIV)	$8.3B
Ascendis Pharma (ASND)	$8.3B
Repligen (RGEN)	$8.1B